Evidence map›Paper›PMID 31551368›Full record

Trial reportJournal of lipid research2019

Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Michael B Boffa, Tanya T Marar, Calvin Yeang, Nicholas J Viney, Shuting Xia, Joseph L Witztum, Marlys L Koschinsky, Sotirios Tsimikas

Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of lipid research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Lipoprotein (a) in primary cardiovascular disease prevention is actionable today.American heart journal plus : cardiology research and practice · 2025
    Review
  10. Review
  11. Article
  12. Lipoprotein(a) and cardiovascular disease.The Biochemical journal · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Michael B BoffaDepartment of Biochemistry Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Tanya T MararDepartment of Biochemistry Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Calvin YeangDivision of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA.
Nicholas J VineyIonis Pharmaceuticals, Carlsbad, CA.
Shuting XiaIonis Pharmaceuticals, Carlsbad, CA.
Joseph L WitztumDivision of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA.
Marlys L KoschinskyRobarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Sotirios TsimikasDivision of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA stsimikas@ucsd.edu.
Ionis Pharmaceuticals (United States) · USWestern University · CAUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is postulated that lipoprotein (a) [Lp(a)] inhibits fibrinolysis, but this hypothesis has not been tested in humans due to the lack of specific Lp(a) lowering agents. Patients with elevated Lp(a) were randomized to antisense oligonucleotide [IONIS-APO(a)

Indexed as

AdolescentAdultAgedFemaleFibrinolysisHumansLipoprotein(a)MaleMiddle AgedOligonucleotides, AntisenseYoung AdultLipoprotein(a)Oligonucleotides, Antisenseapolipoprotein(a)atherosclerotic cardiovascular diseasethrombosis

Identifiers

PMID31551368
PMCPMC6889713
OpenAlexW2976623184

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.